Callos Andrew, an insider at Cytokinetics Inc (CYTK), purchased 51,702 shares on December 7, 2025, at a price of $39.13 per share, totaling $2.02 million. Following this transaction, Andrew holds 51,702 shares of the company.
Cytokinetics, based in South San Francisco, California, focuses on developing muscle activators and inhibitors for treating diseases that compromise muscle performance. The company has a market capitalization of $8.1 billion and reported an earnings per share (EPS) of -6.31 for the trailing twelve months.
The upcoming earnings report is scheduled for May 4, 2026, with an estimated EPS of -1.55 and revenue of $27.4 million. This follows an anticipated EPS of -1.57 and revenue of $36.7 million on August 5, 2026.
Insider transactions like Andrew's provide insights into executive confidence in the company, although they should not be the sole factor in investment decisions. Investors are encouraged to consider patterns of insider activity over time and across multiple insiders for a comprehensive view.